sequential studies with both jurkat-derived il 2 , recombinant il 2 and activated cells were conducted in a total of sixty-seven patients with cancer which established the safety , toxicity and immunologic effects of these treatments prior to their successful combination in humans .
C0021756
recombinant il 2
C0086418
humans